These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25603482)

  • 21. Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
    Heightman TD; Berdini V; Braithwaite H; Buck IM; Cassidy M; Castro J; Courtin A; Day JEH; East C; Fazal L; Graham B; Griffiths-Jones CM; Lyons JF; Martins V; Muench S; Munck JM; Norton D; O'Reilly M; Palmer N; Pathuri P; Reader M; Rees DC; Rich SJ; Richardson C; Saini H; Thompson NT; Wallis NG; Walton H; Wilsher NE; Woolford AJ; Cooke M; Cousin D; Onions S; Shannon J; Watts J; Murray CW
    J Med Chem; 2018 Jun; 61(11):4978-4992. PubMed ID: 29775310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
    Menichincheri M; Bargiotti A; Berthelsen J; Bertrand JA; Bossi R; Ciavolella A; Cirla A; Cristiani C; Croci V; D'Alessio R; Fasolini M; Fiorentini F; Forte B; Isacchi A; Martina K; Molinari A; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pezzetta D; Pillan A; Poggesi I; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jan; 52(2):293-307. PubMed ID: 19115845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit.
    George DM; Breinlinger EC; Friedman M; Zhang Y; Wang J; Argiriadi M; Bansal-Pakala P; Barth M; Duignan DB; Honore P; Lang Q; Mittelstadt S; Potin D; Rundell L; Edmunds JJ
    J Med Chem; 2015 Jan; 58(1):222-36. PubMed ID: 25000588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
    Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
    Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers.
    Zhu GD; Gandhi VB; Gong J; Luo Y; Liu X; Shi Y; Guan R; Magnone SR; Klinghofer V; Johnson EF; Bouska J; Shoemaker A; Oleksijew A; Jarvis K; Park C; Jong RD; Oltersdorf T; Li Q; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3424-9. PubMed ID: 16644221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of potent 1,2,4-trisubstituted imidazolinone derivatives with dual p38αMAPK and ERK1/2 inhibitory activity.
    Awadallah FM; Abou-Seri SM; Abdulla MM; Georgey HH
    Eur J Med Chem; 2015 Apr; 94():397-404. PubMed ID: 25778995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
    Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
    Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
    Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.
    Barlaam B; Cosulich S; Degorce S; Fitzek M; Giordanetto F; Green S; Inghardt T; Hennequin L; Hancox U; Lambert-van der Brempt C; Morgentin R; Pass S; Plé P; Saleh T; Ward L
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3928-35. PubMed ID: 24992874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.
    Lewis RT; Bode CM; Choquette DM; Potashman M; Romero K; Stellwagen JC; Teffera Y; Moore E; Whittington DA; Chen H; Epstein LF; Emkey R; Andrews PS; Yu VL; Saffran DC; Xu M; Drew A; Merkel P; Szilvassy S; Brake RL
    J Med Chem; 2012 Jul; 55(14):6523-40. PubMed ID: 22734674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.
    Defaux J; Antoine M; Logé C; Le Borgne M; Schuster T; Seipelt I; Aicher B; Teifel M; Günther E; Gerlach M; Marchand P
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3748-52. PubMed ID: 25022204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
    Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
    J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
    Arcari JT; Beebe JS; Berliner MA; Bernardo V; Boehm M; Borzillo GV; Clark T; Cohen BD; Connell RD; Frost HN; Gordon DA; Hungerford WM; Kakar SM; Kanter A; Keene NF; Knauth EA; Lagreca SD; Lu Y; Martinez-Alsina L; Marx MA; Morris J; Patel NC; Savage D; Soderstrom CI; Thompson C; Tkalcevic G; Tom NJ; Vajdos FF; Valentine JJ; Vincent PW; Wessel MD; Chen JM
    Bioorg Med Chem Lett; 2013 May; 23(10):3059-63. PubMed ID: 23566514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3).
    Chen H; Yang Z; Ding C; Xiong A; Wild C; Wang L; Ye N; Cai G; Flores RM; Ding Y; Shen Q; Zhou J
    Eur J Med Chem; 2014 Jul; 82():195-203. PubMed ID: 24904966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors.
    Shuai W; Xiao H; Yang P; Zhang Y; Bu F; Wu Y; Sun Q; Wang G; Ouyang L
    J Med Chem; 2024 Apr; 67(8):6425-6455. PubMed ID: 38613499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.
    Bode CM; Boezio AA; Albrecht BK; Bellon SF; Berry L; Broome MA; Choquette D; Dussault I; Lewis RT; Lin MH; Rex K; Whittington DA; Yang Y; Harmange JC
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4089-93. PubMed ID: 22595176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and structure activity relationship study of novel indazole amide inhibitors for extracellular signal-regulated kinase1/2 (ERK1/2).
    Li L; Liu F; Jin N; Tang S; Chen Z; Yang X; Ding J; Geng M; Jiang L; Huang M; Cao J
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2600-4. PubMed ID: 27106711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.
    Jiang X; Zhou J; Ai J; Song Z; Peng X; Xing L; Xi Y; Guo J; Yao Q; Ding J; Geng M; Zhang A
    Eur J Med Chem; 2015 Nov; 105():39-56. PubMed ID: 26476749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.